Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 7/20 | 0.32 |
| ▸ | CA2 | P00918 | 7/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175734 | 0.82 | NOS3 (0.52) | NOS3NOS1NOS2TPSAB1 | |
| SCHEMBL4097713 | 0.77 | KMT2A (0.55) | NOS3NOS1NOS2ALDH1A1TPSAB1 | |
| SCHEMBL430835 | 0.76 | — | — | |
| SCHEMBL13804019 | 0.75 | ALDH1A1 (0.47) | ALDH1A1PAOXLMNASLC15A2CHRM1 | |
| Phosphoric Acid SCHEMBL9074636 | 0.75 | NOS3 (0.46) | NOS3NOS1NOS2TPSAB1CA1 | |
| SCHEMBL4099423 | 0.74 | NOS3 (0.58) | NOS3NOS1NOS2ALDH1A1LMNA | |
| SCHEMBL4093127 | 0.74 | CYP1A2 (0.46) | NOS3NOS1NOS2ALDH1A1LMNA | |
| SCHEMBL4093905 | 0.74 | NOS3 (0.45) | NOS3NOS1NOS2ALDH1A1TPSAB1 | |
| SCHEMBL19133282 | 0.73 | ALDH1A1 (0.45) | ALDH1A1PAOXLMNASLC15A2CHRM1 | |
| SCHEMBL3360466 | 0.72 | NOS3 (0.43) | NOS3NOS1NOS2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202852-B2 | Creatine phosphate analog prodrugs, compositions and uses thereof | XENOPORT, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100137255-A1 | CREATINE PHOSPHATE ANALOG PRODRUGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7683043-B2 | Membrane permeable; ischemia, heart failure, and neurodegenerative disorders | XENOPORT, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080051371-A1 | Membrane permeable; ischemia, heart failure, and neurodegenerative disorders | XENOPORT, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137255-A1 | CREATINE PHOSPHATE ANALOG PRODRUGS, COMPOSITIONS AND USES THEREOF | CKMT1A; CKMT1B, PYGM, TNNI3 | NOS3 2619/4885NOS1 3178/4885NOS2 3005/4885 |
| US-20080051371-A1 | Membrane permeable; ischemia, heart failure, and neurodegenerative disorders | CKMT1A; CKMT1B, SLC8B1, SLC2A1 | NOS3 1610/4885NOS1 2008/4885NOS2 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.